China
· Delayed Price · Currency is CNY Shenzhen Hepalink Pharmaceutical Group Statistics
Total Valuation
Shenzhen Hepalink Pharmaceutical Group has a market cap or net worth of CNY 14.53 billion. The enterprise value is 16.53 billion.
| Market Cap | 14.53B |
| Enterprise Value | 16.53B |
Important Dates
The next estimated earnings date is Monday, October 28, 2024.
| Earnings Date | Oct 28, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Shenzhen Hepalink Pharmaceutical Group has 1.47 billion shares outstanding. The number of shares has decreased by -0.01% in one year.
| Shares Outstanding | 1.47B |
| Shares Change (YoY) | -0.01% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 1.64% |
| Owned by Institutions (%) | 2.32% |
| Float | 455.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 22.56 |
| PS Ratio | 2.88 |
| PB Ratio | 1.32 |
| P/FCF Ratio | 8.73 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 52.45, with an EV/FCF ratio of 8.99.
| EV / Earnings | -68.05 |
| EV / Sales | 2.97 |
| EV / EBITDA | 52.45 |
| EV / EBIT | n/a |
| EV / FCF | 8.99 |
Financial Position
The company has a current ratio of 2.39, with a Debt / Equity ratio of 0.38.
| Current Ratio | 2.39 |
| Quick Ratio | 0.97 |
| Debt / Equity | 0.38 |
| Debt / EBITDA | 14.58 |
| Debt / FCF | 2.50 |
| Interest Coverage | -0.19 |
Financial Efficiency
Return on equity (ROE) is -2.12% and return on invested capital (ROIC) is -0.13%.
| Return on Equity (ROE) | -2.12% |
| Return on Assets (ROA) | -0.11% |
| Return on Capital (ROIC) | -0.13% |
| Revenue Per Employee | 2.68M |
| Profits Per Employee | -116,791 |
| Employee Count | 2,080 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 0.65 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1.07% in the last 52 weeks. The beta is 0.48, so Shenzhen Hepalink Pharmaceutical Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | +1.07% |
| 50-Day Moving Average | 9.98 |
| 200-Day Moving Average | 9.67 |
| Relative Strength Index (RSI) | 58.63 |
| Average Volume (20 Days) | 5,195,753 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Shenzhen Hepalink Pharmaceutical Group had revenue of CNY 5.57 billion and -242.92 million in losses. Loss per share was -0.17.
| Revenue | 5.57B |
| Gross Profit | 985.69M |
| Operating Income | -35.58M |
| Pretax Income | -328.41M |
| Net Income | -242.92M |
| EBITDA | 282.45M |
| EBIT | -35.58M |
| Loss Per Share | -0.17 |
Balance Sheet
The company has 2.67 billion in cash and 4.60 billion in debt, giving a net cash position of -1.93 billion or -1.32 per share.
| Cash & Cash Equivalents | 2.67B |
| Total Debt | 4.60B |
| Net Cash | -1.93B |
| Net Cash Per Share | -1.32 |
| Equity (Book Value) | 12.21B |
| Book Value Per Share | 8.27 |
| Working Capital | 6.23B |
Cash Flow
In the last 12 months, operating cash flow was 2.24 billion and capital expenditures -396.42 million, giving a free cash flow of 1.84 billion.
| Operating Cash Flow | 2.24B |
| Capital Expenditures | -396.42M |
| Free Cash Flow | 1.84B |
| FCF Per Share | 1.25 |
Margins
Gross margin is 17.70%, with operating and profit margins of -0.64% and -4.36%.
| Gross Margin | 17.70% |
| Operating Margin | -0.64% |
| Pretax Margin | -5.90% |
| Profit Margin | -4.36% |
| EBITDA Margin | 5.07% |
| EBIT Margin | -0.64% |
| FCF Margin | 33.02% |
Dividends & Yields
Shenzhen Hepalink Pharmaceutical Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | 185.71% |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | 0.01% |
| Shareholder Yield | 0.01% |
| Earnings Yield | -1.51% |
| FCF Yield | 11.46% |
Stock Splits
The last stock split was on June 13, 2016. It was a forward split with a ratio of 1.6.
| Last Split Date | Jun 13, 2016 |
| Split Type | Forward |
| Split Ratio | 1.6 |
Scores
Shenzhen Hepalink Pharmaceutical Group has an Altman Z-Score of 2.37. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.37 |
| Piotroski F-Score | n/a |